Navigation Links
Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program

SAN DIEGO, Oct. 7 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) and AnGes MG, Inc., have signed a non-binding Letter of Intent indicating their mutual interest to license the development and marketing rights for Vical's pandemic influenza DNA vaccines in Japan to AnGes. AnGes plans to conduct due diligence on the pandemic influenza DNA vaccines, and both parties intend to negotiate terms and conditions potentially leading to a license, subject to completion of a mutually satisfactory definitive agreement.

Japan's geographic proximity to many of the avian influenza outbreaks in recent years puts the country at high risk for future outbreaks. The Japanese Ministry of Health, Labor and Welfare has estimated that the emergence of a new strain of influenza could lead to 13 to 25 million infections and 170,000 to 640,000 deaths in Japan. AnGes' experience in working with Vical's DNA delivery technology within the Japanese regulatory environment positions the company well to pursue further development in Japan based on Vical's recently announced preliminary Phase 1 H5N1 pandemic influenza data.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about a Letter of Intent to negotiate terms and conditions potentially leading to a license agreement with AnGes for development and marketing of pandemic influenza DNA vaccines in Japan, as well as Vical's focus, collaborative partners, and product candidates. Risks and uncertainties include whether we will be able to complete a mutually satisfactory definitive agreement with AnGes; whether preliminary H5N1 DNA vaccine Phase 1 clinical trial results will be confirmed upon further analysis or in larger studies; whether any product candidates under development by Vical or its collaborative partners will be shown to be safe and effective in clinical trials; the timing, nature and cost of clinical trials; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; whether Vical or its collaborative partners will succeed in marketing any product candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Contact: Alan R. Engbring

(858) 646-1127


SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vical to Present at UBS Global Life Sciences Conference
2. Society of Gynecologic Oncologists to Host Cervical Cancer Prevention Forum
3. Pioneer(R) Surgical Technology, Inc. Announces the Market Launch of the SlimFuse(TM) Anterior Cervical Plate System
4. Vical to Present at Upcoming Investor Conferences
5. Pioneer(R) Surgical Technology Announces First Human Implants of its NuNec(TM) Cervical Arthroplasty Device
6. Vical Announces News Release and Conference Call Schedule for First Quarter 2008 Financial Results
7. One4One Campaign to Raise $1 Million to Improve Cervical Cancer Education and Resources
8. Vical Licensee AnGes MG Files NDA in Japan for Collategene Angiogenesis Product
9. Vical to Present at Cowen and Company Health Care Conference
10. Vical to Present at BIO and BVGH Global Health Partnering Event
11. Survey Shows Most Women Cant Separate Fact From Fiction When It Comes to Cervical Cancer Prevention
Post Your Comments:
(Date:12/1/2015)... 2015 Cepheid (Nasdaq: CPHD ) today ... Piper Jaffray Healthcare Conference in New York ... reaffirming its outlook for the fourth quarter of 2015 ... discussing longer term business model expectations. John ... continue to be the fastest growing company of the ...
(Date:12/1/2015)... 1, 2015 ... "2016 U.K. Virology and Bacteriology Testing Market: ... Tests, Supplier Shares by Test, Innovative Technologies, ... offering.  --> ) has ... Virology and Bacteriology Testing Market: Sales and ...
(Date:11/30/2015)... ... ... Global Stem Cells Group announced the opening of a new core patient care ... in northern Chile. The facilities are part of GSCG’s expansion efforts in Latin America. ... stem cell medicine to patients from around the world. , The clinics will be headed ...
(Date:11/30/2015)... 30, 2015  Culprits beware, a University at ... Jan Halámek, is taking crime scene fingerprint identification ...   -->   --> ... --> --> Halámek and ... a straightforward concept for identifying whether a culprit ...
Breaking Biology Technology:
(Date:11/12/2015)... golden retriever that stayed healthy despite having the gene ... new lead for treating this muscle-wasting disorder, report scientists ... and Harvard and the University of São Paolo in ... pinpoints a protective gene that boosts muscle regeneration, ... Children,s lab of Lou Kunkel , PhD, is ...
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
(Date:11/4/2015)... 2015 --> ... by Transparency Market Research "Home Security Solutions Market - Global ... - 2022", the global home security solutions market is expected to ... The market is estimated to expand at a CAGR ... 2022. Rising security needs among customers at homes, the ...
Breaking Biology News(10 mins):